AxoGen - AXGN Stock Forecast, Price & News

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AxoGen in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AXGN shares.
View AXGN analyst ratings or view top-rated stocks.

3 equities research analysts have issued 12 month price targets for AxoGen's stock. Their AXGN share price forecasts range from $15.00 to $18.00. On average, they anticipate the company's share price to reach $16.00 in the next twelve months. This suggests a possible upside of 44.3% from the stock's current price.
View analysts price targets for AXGN or view top-rated stocks among Wall Street analysts.

AxoGen's stock was trading at $9.37 on January 1st, 2022. Since then, AXGN stock has increased by 18.4% and is now trading at $11.09.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 28th 2023.
View our AXGN earnings forecast.

AxoGen, Inc. (NASDAQ:AXGN) issued its earnings results on Tuesday, November, 2nd. The medical equipment provider reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.05. The medical equipment provider earned $31.20 million during the quarter, compared to analyst estimates of $34.65 million. AxoGen had a negative net margin of 21.51% and a negative trailing twelve-month return on equity of 18.09%. During the same quarter in the prior year, the company earned ($0.04) earnings per share.

AxoGen issued an update on its FY 2022 earnings guidance on Tuesday, November, 8th. The company provided EPS guidance of for the period. The company issued revenue guidance of $137.50 million-$140.00 million, compared to the consensus revenue estimate of $139.34 million.

19 employees have rated AxoGen Chief Executive Officer Karen Zaderej on Glassdoor.com. Karen Zaderej has an approval rating of 100% among the company's employees. This puts Karen Zaderej in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 83.0% of employees surveyed would recommend working at AxoGen to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other AxoGen investors own include Advanced Micro Devices (AMD), Bank of America (BAC), Intelsat (I), Intel (INTC), Micron Technology (MU), Xilinx (XLNX), Corbus Pharmaceuticals (CRBP), Exelixis (EXEL), NVIDIA (NVDA) and Fossil Group (FOSL).

AxoGen trades on the NASDAQ under the ticker symbol "AXGN."

AxoGen's stock is owned by a number of institutional and retail investors. Top institutional shareholders include First Light Asset Management LLC (6.89%), BlackRock Inc. (6.87%), Point72 Asset Management L.P. (5.12%), Vanguard Group Inc. (4.51%), Perceptive Advisors LLC (2.25%) and State Street Corp (1.97%). Insiders that own company stock include Angelo Scopelianos, Erick Wayne Devinney, Gregory Gene Freitag, Isabelle Billet, Karen L Zaderej, Karen L Zaderej, Maria D Martinez, Michael Patrick Donovan and Peter J Mariani.
View institutional ownership trends.

Shares of AXGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AXGN stock can currently be purchased for approximately $11.09.

AxoGen (NASDAQ:AXGN) has a market capitalization of $469.00 million and generates $127.36 million in revenue each year. The medical equipment provider earns $-26,990,000.00 in net income (profit) each year or ($0.68) on an earnings per share basis.

The company employs 428 workers across the globe.

AxoGen's mailing address is 13631 PROGRESS BLVD. SUITE 400, ALACHUA FL, 32615. The official website for the company is www.axogeninc.com. The medical equipment provider can be reached via phone at (386) 462-6800, via email at investorrelations@axogeninc.com, or via fax at 386-462-6801.